APA (7th ed.) Citation

BR, W., SB, H., CJ, P., JE, D., HA, A., P, S., . . . RM, S. (2020). Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. Molecular cancer therapeutics, 19(11), 2308. https://doi.org/10.1158/1535-7163.MCT-19-0858

Chicago Style (17th ed.) Citation

BR, Wei, et al. "Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual MTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma." Molecular Cancer Therapeutics 19, no. 11 (2020): 2308. https://doi.org/10.1158/1535-7163.MCT-19-0858.

MLA (9th ed.) Citation

BR, Wei, et al. "Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual MTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma." Molecular Cancer Therapeutics, vol. 19, no. 11, 2020, p. 2308, https://doi.org/10.1158/1535-7163.MCT-19-0858.